| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ... New England Journal of Medicine 353 (16), 1659-1672, 2005 | 6567 | 2005 |
| Triple-negative breast cancer WD Foulkes, IE Smith, JS Reis-Filho New England journal of medicine 363 (20), 1938-1948, 2010 | 4572 | 2010 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4317 | 2013 |
| Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 JG Doench, N Fusi, M Sullender, M Hegde, EW Vaimberg, KF Donovan, ... Nature biotechnology 34 (2), 184-191, 2016 | 3776 | 2016 |
| A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2552 | 2017 |
| A layered hybrid perovskite solar‐cell absorber with enhanced moisture stability IC Smith, ET Hoke, D Solis‐Ibarra, MD McGehee, HI Karunadasa Angewandte Chemie International Edition 53 (42), 11232-11235, 2014 | 2325 | 2014 |
| Programming the finite element method IM Smith, DV Griffiths, L Margetts John Wiley & Sons, 2013 | 2261 | 2013 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2234 | 2015 |
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ... Journal of the National cancer Institute 103 (22), 1656-1664, 2011 | 2030 | 2011 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1955 | 2007 |
| Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation JG Doench, E Hartenian, DB Graham, Z Tothova, M Hegde, I Smith, ... Nature biotechnology 32 (12), 1262-1267, 2014 | 1749 | 2014 |
| Place lab: Device positioning using radio beacons in the wild A LaMarca, Y Chawathe, S Consolvo, J Hightower, I Smith, J Scott, ... Pervasive Computing: Third International Conference, PERVASIVE 2005, Munich …, 2005 | 1649 | 2005 |
| Activity sensing in the wild: a field trial of ubifit garden S Consolvo, DW McDonald, T Toscos, MY Chen, J Froehlich, B Harrison, ... Proceedings of the SIGCHI conference on human factors in computing systems …, 2008 | 1511 | 2008 |
| MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy GW Sledge Jr, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... Journal of clinical oncology 35 (25), 2875-2884, 2017 | 1476 | 2017 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Journal of Clinical Oncology 35 (32), 3638-3646, 2017 | 1467 | 2017 |
| Aromatase inhibitors in breast cancer IE Smith, M Dowsett New England Journal of Medicine 348 (24), 2431-2442, 2003 | 1237 | 2003 |
| Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer I Garcia-Murillas, G Schiavon, B Weigelt, C Ng, S Hrebien, RJ Cutts, ... Science translational medicine 7 (302), 302ra133-302ra133, 2015 | 1192 | 2015 |
| Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology I Smith, P Kranke, I Murat, A Smith, G O'Sullivan, E Søreide, C Spies European Journal of Anaesthesiology| EJA 28 (8), 556-569, 2011 | 1165 | 2011 |
| Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 AS Coates, A Keshaviah, B Thürlimann, H Mouridsen, L Mauriac, ... Journal of clinical oncology 25 (5), 486-492, 2007 | 1148 | 2007 |
| Design requirements for technologies that encourage physical activity S Consolvo, K Everitt, I Smith, JA Landay Proceedings of the SIGCHI conference on Human Factors in computing systems …, 2006 | 1138 | 2006 |
